anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is \> 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is \< 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches \> 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
FIELD: immunology. SUBSTANCE: invention relates to monoclonal antibodies recognizing extracellular human glycoprotein P epitope that involves specific epitope-forming amino acid sequence, preferably located in the fourth extracellular loop of human glycoprotein P and, especially, containing in peptide composition corresponding to the Sequence 1. Preferable antibodies bind human glycoprotein P specifically and at high efficiency and can be used for detection of human "MYA"-cells presented at very low part of cell population and producing human glycoprotein P at very small amount. Indicated antibodies can be the whole antibodies or their antigen-binding fragment and can be prepared by hybridoma technique or recombinant DNA. Monoclonal antibodies are useful for detection and purification of cell producing human glycoprotein P, in part, when they present in heterogeneous cell population and also for testing multiple resistance to antibiotics in cells, for example, tumor cells. EFFECT: improved method of preparing, enhanced effectiveness of test.
Hypersensitivity to any component of this medication.

Active liver disease or unexplained, persistent elevations of serum transaminases (see WARNINGS).

Pregnancy and Lactation: Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they are contraindicated during pregnancy and in nursing mothers. Pravastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this class of drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus (see PRECAUTIONS: Pregnancy).
For the control arm, the patients will be monitored for one year with the same standard assessments used for the measurement of seizure frequency and severity. No changes will be made to these patients' treatment plan. These patients will be placed on a wait list for CM-DBS treatment of seizures if that is the desire of the patient and/or their family. After the 12 months of observation, these patients can choose to undergo DBS surgery.
Ovarian cancer (OC) is a significant cause of cancer-related mortality in women worldwide. Despite advances in treatment modalities, including surgery and chemotherapy, the overall prognosis for OC patients remains poor, particularly for patients with advanced or recurrent disease. Immunotherapy, particularly immune checkpoint blockade (ICB), has revolutionized cancer treatment in various malignancies but has shown limited efficacy in treating OC, which is primarily attributed to the immunologically. Tertiary lymphoid structures (TLSs), which are ectopic aggregates of immune cells, have emerged as potential mediators of antitumor immunity. This review explores the composition, formation, and induction of tumor associated TLS (TA-TLS) in OC, along with their role and therapeutic implications in disease development and treatment. By elucidating the roles TA-TLSs and their cellular compositions played in OC microenvironment, novel therapeutic targets may be identified to overcome immune suppression and enhance immunotherapy efficacy in ovarian cancer.
The invention concerns the use of a virus for the preparation of a medicament for thevaccination or treatment of a neonatal or prenatal animal, including a human,wherein the virus is capable of infecting the cells of the neonatal or prenatal animal,including a human, but not capable of being replicated to infectious progeny virus inthe neonatal or prenatal animal, including a human. The virus is preferably aModified Vaccinia Virus Ankara. In particular, the invention concerns the vaccinationof neonates against infections with viruses belonging the same virus group than thevirus used for vaccination. Moreover, the invention concerns the vaccination ofneonates against antigens selected from foreign antigens and tumour antigens,wherein the tumour antigen and/or the foreign antigen are different from the antigensassociated with the virus. The invention further concerns the use of viruses asdefined above to increase the level of factors which activate dendritic cells or theirprecursor cells and/or to increase the number of dendritic cells or their precursorcells and/or to increase the production and/or cellular content of an interferon (IFN)or IL-12.(no suitable figure)
FIELD: medicine; ophthalmology.SUBSTANCE: group of inventions relates to the field of medicine, namely to ophthalmology; it is intended for the treatment of a complement-mediated ocular disorder, namely age-related macular dystrophy (hereinafter – AMD). A method for the treatment of a complement-mediated ocular disorder includes the injection to a subject who needs it of a long-acting compstatin analog (hereinafter – LACA). The specified LACA contains a clearance-reducing fragment connected to two compstatin analog fragments, wherein each compstatin analog fragment contains cyclic peptide with an amino acid sequence represented in SEQ ID NO: 28, elongated with lysin residue at C-end, wherein lysin residue is separated from a cyclic part with 8-amino-3,6-dioxaoctanoic acid (AEEAc)-spacer. The specified clearance-reducing fragment contains polymer, wherein each polymer end is bound to an amino group of a side chain of lysin residue of one of compstatin analog fragments via carbamate, and polymer is PEG with an average molecular weight of 40 kDa. The specified complement-mediated ocular disorder is AMD. The specified treatment includes intravitreal injection once a month or once every two months of the specified LACA to the eye of the specified subject in the amount from 10 mg to 20 mg. In other embodiments, the use of LACA in the treatment of AMD, and the use of a single dosed form of LACA in the treatment of AMD in a subject who needs it are presented.EFFECT: use of the group of inventions provides for a new therapeutic mode for the effective treatment of a complement-mediated ocular disorder, such as AMD.25 cl, 12 dwg, 12 tbl, 28 ex
Dental plaque removal is essential in maintaining oral health. Methods for oral hygiene vary from country to country and from culture to culture. The use of a wood stick (miswak or chewing stick) for brushing the teeth is considered an important tool for oral hygiene care in many Afro-Asian communities. The aim of the study is to compare the effect of the chewing stick (miswak), and toothbrushing on plaque removal and gingival health. The participants comprise 18 healthy Saudi Arabian male volunteers aged 21 to 30 years, at Taibah University in Saudi Arabia. The study was designed as a single, blind, randomized split-mouth study. Professional tooth cleaning was conducted, and after six weeks use of either the miswak or toothbrush on each quadrant, modified plaque and gingival indices, were recorded.
The invention belongs to the field of biological materials, and particularly relates to a gel preparation containing adipose-derived stem cells and a preparation method and surgical dressing thereof. The gel preparation comprises the adipose-derived stem cells, albumin, gelatin and solvent. The adipose-derived stem cells, the albumin, the gelatin and the solvent are creatively adopted for being made into the stem cell gel preparation. Intravenous reinjection is needless in the using process of the preparation, the preparation only needs to be applied to a wound for simple dressing, and accordingly a remediation effect on the wound can be achieved. For the reason that the stem cell gel preparation does not need to be applied in an intravenous reinjection mode, the phenomenon that a large number of stem cells in the preparation run away due to intravenous reinjection is avoided, and the stem cell gel preparation has the good wound remediation effect. Experimental results show that after the surgical dressing of the gel preparation is applied to the surface of the wound, the 7d wound healing rate is larger than 80+/-7%. It is suggested that the gel preparation has the good remediation effect on the wound.
The invention relates to a Chinese traditional medicine patch, namely Baimaiyutong Patch. The patch is prepared from the following raw materials by the following weight parts: 5 to 60 grams of leech, 5 to 30 grams of eupolyphaga seu steleophaga, 20 to 40 grams of myrrh, 5 to 15 grams of madder, 2 to 20 grams of safflower, 10 to 50 grams of phellodendron bark, and 5 to 20 grams of borneol. The patch has the functions of expelling wind and removing damness, promoting blood circulation by removing blood stasis, anti-inflammation and detumescence, restoring menstrual flow and activating channels and collaterals. The patch is used for primarily cure varicosity, traumatic injuries and sprain, and lumbar disc heriation rupture of the lumbarintervertebral disk. The formula of the patch is simple, and the raw materials are matched reasonably; the time for applying the patch is short; the patch has remarkable curative effect with high cure rate; the pain resulting from surgical operation is reduced. Proven through the tests of the patch on 283 sufferers of lumbar disc heriation rupture of the lumbarintervertebral disk, the patch takes effect quickly, and the function of the patch lasts for long; the patch has small toxic and side effect with the total effective percentage more than 97.7 percent.
University life poses various challenges for students, such as being away from family, financial difficulties, and exam anxiety, which can increase stress levels. Test anxiety, a form of situation-specific anxiety, negatively impacts students' academic performance and well-being by reducing concentration and learning efficiency. The combination of theoretical and clinical demands in nursing education further amplifies stress, making it a particularly challenging field for students.

This study is a randomized controlled experimental research conducted between December 2, 2024, and January 13, 2025. The study population consists of nursing students enrolled in the Mental Health and Psychiatric Nursing course at a private university during the 2024-2025 academic year. Based on sample size calculations conducted using the G\*Power program, considering similar studies and measurement methods, it was determined that 26 students per group are required. Accounting for potential data loss, it is planned to conduct the study with a total of 62 students, 32 in each group.

Students will be informed about the research, and those who voluntarily agree to participate will complete a "Demographic Characteristics Form" and a pre-test using the "Test Anxiety Inventory." Subsequently, students will be randomly assigned to the intervention and control groups in a 1:1 ratio using a random numbers table, with 31 students in each group. Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period. Email reminders will be sent to the students about the coloring sessions, and they will submit their completed mandalas to the researchers every Friday. Students who fail to complete two consecutive coloring sessions will be excluded from the study. Thirty minutes before the exam, the "Test Anxiety Inventory" will be applied as a post-test, and the study will be concluded. The data obtained will be subjected to statistical analysis, and the process of writing the manuscript will follow.
This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
Reproductive Toxicology Studies: In mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above (less than the maximum recommended daily inhalation dose in adults on an mcg/m2 basis). Fetal survival was reduced at 180 mcg/kg (approximately equal to the maximum recommended daily inhalation dose in adults on an mcg/m2 basis). No toxicity was observed at 20 mcg/kg (less than the maximum recommended daily inhalation dose in adults on an mcg/m2 basis).

In rats, mometasone furoate produced umbilical hernia at topical dermal doses of 600 mcg/kg and above (approximately 6 times the maximum recommended daily inhalation dose in adults on an mcg/m2 basis). A dose of 300 mcg/kg (approximately 3 times the maximum recommended daily inhalation dose in adults on an mcg/m2 basis) produced delays in ossification but no malformations.

When rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg (approximately 6 times the maximum recommended daily inhalation dose in adults on an AUC basis) caused prolonged and difficult labor and reduced the number of live births, birth weight, and early pup survival. Similar effects were not observed at 7.5 mcg/kg (approximately 3 times the maximum recommended daily inhalation dose in adults on an AUC basis).

In rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at topical dermal doses of 150 mcg/kg and above (approximately 3 times the maximum recommended daily inhalation dose in adults on an mcg/m2 basis). In an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg (less than the maximum recommended daily inhalation dose in adults on an area under the curve [AUC] basis). At 2800 mcg/kg (approximately 2 times the maximum recommended daily inhalation dose in adults on an AUC basis) most litters were aborted or resorbed. No toxicity was observed at 140 mcg/kg (less than the maximum recommended daily inhalation dose in adults on an AUC basis).
The investigators will recruit patient from the VA pacemaker/ implantable cardioverter defibrillator clinic. Patients with ICDs will be identified before scheduled clinical visit. Patients whose ICDs on remote monitoring show evidence of VT/VF and who are being admitted to the VA medical center for expedited inpatient work up and treatment will also be offered enrollment in the study. Patients will be approached and educated about the study rationale and their involvement. Patients will be consented for participation in the study after their approval. Patients will be educated about donating fecal samples. Patients will be given fecal sampling kits to collect and subsequently mail in those samples to the University of Florida physiology laboratory where there will be processed in a HIPAA compliant way. These samples will be subjected to laboratory analysis which will be outsourced. Fecal samples will be analyzed by shotgun metagenomics to characterize the taxonomy of the gut flora and compare the taxonomic and physiologic differences between the groups.
The carbo-dissection technique is performed using an improvised instrument that combines an electrocautery pencil (ValleylabTM Force FX electrocautery Pencil, Covidien, USA) with a CO2 mister blower (PerfX® Heart Lung pack Blower/Mister Kit, B L Lifesciences, Noida, India) and the instruments are fixed together using silk ties.The electrocautery is used in the coagulation mode at a setting of 10 to 15. The C02 flow is set at 2 to 3 litres/minute. Saline flow is adjusted to a level that does not hinder the effective coagulation but still prevents drying and desiccation of the tissues. Following the dissection of LIMA by the techniques mentioned above, blood flow from the harvested LIMA for one whole minute was noted(1 min post division of LIMA). The operative time required for LIMA dissection was also noted and entered. Patient's s demographic data were also collected and entered.
PURPOSE:To obtain the titled external preparation comprising urinostatin as an active ingredient. CONSTITUTION:An external preparation for treating allergic diseases comprising urinastatin (trypsin inhibitor in human urine: acidic glycoprotein having about 67,000mol.wt., pH 2-3 isoelectric point and 5-12% saccharide; inhibiting not only proteolytic enzyme such as trypsin and alpha-chymotrypsin but also enzymes hydrolyzing saccharides and lipids such as hyaluronidase and lipase and showing a wide inhibitory spectrum). The preparation is effective especially against allergic rhinitis and allergic conjunctivitis. A dose is 1,000-100,000 u, preferably 5,000-100,000 u daily. A freeze-dried agent is used as the dosage form, is dissolved when used and sprayed upon nasal cavity by a nebulizer or used as an eye dropper or a nasal drop. Or the preparation is made into capsules and sprayed in powder state.
The invention discloses acupuncture liquid medicine for curing vascular type cervical spondylosis and a preparation method of the acupuncture liquid medicine. The acupuncture liquid medicine is prepared from the following raw materials in parts by weight: 29-31 parts of herba lycopodii, 29-31 parts of herba phryma leptostachya, 29-31 parts of herba schizonepetae, 29-31 parts of radix saposhnikoviae, 29-31 parts of radix aconiti carmichaeli, 29-31 parts of cortex erythrinae, 29-31 parts of rhizoma homalomenae, 29-31 parts of radix clematidis, 29-31 parts of cinnamomi ramulus, 29-31 parts of radix notopterygii, 29-31 parts of fructus liquidambaris, 29-31 parts of radix angelicae pubescentis, 29-31 parts of herba ephedrae, 29-31 parts of flos carthami and 299-301 parts of fructus euodiae. The medical materials which are prepared according to the medicine ingredients and parts by weight are cut into slices, then evenly mixed with 144 parts of vinegar, stood and moistened. After the vinegar is absorbed completely, the medical materials are arranged in a heating container to be fried in a temperature of 150-170 DEG C. When the surfaces of the medical materials become yellow or deep color, the medical materials are taken out and aired. The dry medical materials are smashed to 30-35 mesh particles, 720 parts of baijiu with alcoholic content of 70-75% are added, the medical materials are soaked for 3-5 days, and the liquid medicine can be obtained after the medical materials are filtered out. The liquid medicine can be matched with acupuncture to relax the muscles, stimulate the blood and break through main and collateral channels. The liquid medicine is free of toxic and side effect, quick in curing effect, obvious in curing effect and suitable for vascular type cervical spondylosis patients.
FASTRACK is a 2 -cohort, non-randomised prospective feasibility study. Anticipated total duration of accrual is approximately 24 months, with all patients expected to complete all protocol treatment and imaging within a further 3 months. The trial will close after the last patient has completed his/her last protocol related follow-up visit (at 12 months post-treatment).

Cohort 1: patients with renal cell carcinoma within the kidney Cohort 2: patients with solitary adrenal metastases from non-small cell lung carcinoma The investigational treatment will be prescribed the covering isodose, ensuring that 99% of the PTV is covered by 100% of the dose (D99=100%). It is anticipated that most treatments should be highly conformal. Treatment must be delivered with at least six (6) non-opposing conformal megavoltage photon beams. It is anticipated that a typical range of beam numbers would be 8 to 12, comprising of at least 6 co-planar beams and 1-2 non-coplanar beams. No cytotoxic chemotherapy is allowed within 3 weeks or concurrently with respect to the investigational treatment. Consultation with the treating radiation oncologist is strongly recommended if chemotherapy is to be considered after the investigational treatment and before documented disease progression, to prevent unforeseen combined toxicities. Targeted agents (such as sunitinib) are exempt from this recommendation.
<P>PROBLEM TO BE SOLVED: To provide an improved bio-material and a method for the restoration or replacement of a tissue.  <P>SOLUTION: A peptide scaffold is provided for the restoration and the replacement of various tissues. The invention further provides a method for producing the scaffold and a method for using them. The invention is characterized by the scaffold which has an amphipatic peptide with a bio-cell incorporated and can be seen with the naked eye. The peptide alternately includes an aqueous amino acid and hydrophilic amino acid, is supplementary and compatible in structure and is autonomously assembled to the scaffold which can be seen with the β-sheet type naked eye. The scaffold which can be seen with the naked eye encapsulates the bio-cell. Then, the encapsulated cell exists in the scaffold with a three-dimensional arrangement which can be seen with the naked eye.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Acute renal failure (ARF) is a frequent complication in sepsis, in nearly to 50% of the cases, and the mortality rate is higher, compare to patients with ARF alone (70% vs 45%). Clinical and experimental studies demonstrated the key role of apoptosis, or programmed cell death, in the induction of tubular and glomerular injury in the course of sepsis. Indeed, it has been shown that inflammatory cytokines and lipopolysaccharide (LPS) cause renal tubular cell apoptosis via Fas- and caspase-mediated pathways. In addition, LPS is able to alter the normal expression pattern of sodium, urea and glucose renal transporters and to modulate tubular polarity by changing the expression of tight junction proteins with consequent back-leakage of tubular fluid in the interstitial spaces and enhancement of the inflammatory process. Therefore a novel extracorporeal therapy to remove circulating LPS, using the Polymyxin-B fiber (PMX-B) cartridge was developed. The PMX-B cartridge is an extracorporeal hemoperfusion device and consists of a polystyrene-based, fibrous adsorbent on which the polymyxin B antibiotic is covalently immobilized as a ligand to adsorb endotoxin.

Aim of this study is to verify whether the removal of LPS, using the PMX-B hemoperfusion system, protects from acute renal failure, reduces the need for Renal Replacement Therapy (RRT) and consequently improves the outcome in severe sepsis from gram negative infection.
Healthy / control participants with normal vision will be volunteers, selected after interview (inclusion assessment). Their recruitment will be carried out on the basis of advertisements displayed at Grenoble Alpes University. Patients will be volunteers, selected on the basis of their ophthalmological clinical record. Their recruitment will be done at the Ophthalmology Clinic of the University Hospital of Grenoble (through Professor Florent Aptel). For all the participants, a medical examination before MRI examination will be carried out in the MRU unit of the CHU of Grenoble in order to verify the eligibility criteria for contraindications to MRI and MRI scanning. The results of these examinations will be communicated to the subjects prior to the expression of their consent directly or through the doctor of their choice.